Identification of biochemical pathways for the metabolism of oxidized low-density lipoprotein derived aldehyde-4-hydroxy trans-2-nonenal in vascular smooth muscle cells.
Oxidation of low-density lipoproteins (LDL) generates high concentrations of unsaturated aldehydes, such as 4-hydroxy trans-2-nonenal (HNE). These aldehydes are mitogenic to vascular smooth muscle cells and sustain a vascular inflammation. Nevertheless, the processes that mediate and regulate the vascular metabolism of these aldehydes have not been examined. In this communication, we report the identification of the major metabolic pathways and products of [(3)H]-HNE in rat aortic smooth muscle cells in culture. High-performance liquid chromatography separation of the radioactivity recovered from these cells revealed that a large (60-65%) proportion of the metabolism was linked to glutathione (GSH). Electrospray mass spectrometry showed that glutathionyl-1,4 dihydroxynonene (GS-DHN) was the major metabolite of HNE in these cells. The formation of GS-DHN appears to be due aldose reductase (AR)-catalyzed reduction of glutathionyl 4-hydroxynonanal (GS-HNE), since inhibitors of AR (tolrestat or sorbinil) prevented GS-DHN formation, and increased the fraction of the glutathione conjugate remaining as GS-HNE. Gas chromatography-chemical ionization mass spectroscopy of the metabolites identified a subsidiary route of HNE metabolism leading to the formation of 4-hydroxynonanoic acid (HNA). Oxidation to HNA accounted for 25-30% of HNE metabolism. The formation of HNA was inhibited by cyanamide, indicating that the acid is derived from an aldehyde dehydrogenase (ALDH)-catalyzed pathway. The overall rate of HNE metabolism was insensitive to inhibition of AR or ALDH, although inhibition of HNA formation by cyanamide led to a corresponding increase in the fraction of HNE metabolized by the GSH-linked pathway, indicating that ALDH-catalyzed oxidation competes with glutathione conjugation. These metabolic pathways may be the key regulators of the vascular effects of HNE and oxidized LDL.
Srivastava
S
S
Experimental Research Laboratories, Division of Cardiology, University of Louisville, and Jewish Hospital Heart and Lung Institute, Louisville, KY 40202, USA.
Conklin
D J
DJ
Liu
S Q
SQ
Prakash
N
N
Boor
P J
PJ
Srivastava
S K
SK
Bhatnagar
A
A
D000449:Aldehyde Reductase / Q000037:antagonists & inhibitors / Q000378:metabolism; D000447:Aldehydes / Q000378:metabolism*; D000475:Alkenes / Q000378:metabolism; D000818:Animals; D001011:Aorta / Q000378:metabolism; D002478:Cells, Cultured; D002851:Chromatography, High Pressure Liquid; D004791:Enzyme Inhibitors / Q000494:pharmacology; D005978:Glutathione / Q000378:metabolism; D007093:Imidazoles / Q000494:pharmacology; D048289:Imidazolidines; D008077:Lipoproteins, LDL / Q000378:metabolism*; D008297:Male; D013058:Mass Spectrometry; D009131:Muscle, Smooth, Vascular / Q000378:metabolism*; D009281:Naphthalenes; D051381:Rats; D017207:Rats, Sprague-Dawley
C091765:1,4-dihydroxy-2-nonene; D000447:Aldehydes; D000475:Alkenes; D004791:Enzyme Inhibitors; D007093:Imidazoles; D048289:Imidazolidines; D008077:Lipoproteins, LDL; D009281:Naphthalenes; C099252:oxidized low density lipoprotein; C040550:tolrestat; D000449:Aldehyde Reductase; C026411:sorbinil; D005978:Glutathione; C027576:4-hydroxy-2-nonenal